Infectious Complications in Adults Undergoing Intensive Chemotherapy for Acute Myeloid Leukemia in 2001-2005 Using the Japan Adult Leukemia Study Group AML201 Protocols

Overview

Journal Support Care Cancer

Specialties Critical Care
Oncology

Date 2018 Jun 4

PMID 29860713

Citations 6

Authors

Hideaki Kato

Hiroyuki Fujita

Nobu Akiyama

Shun-Ichi Kimura

Nobuhiro Hiramoto

Naoko Hosono

Tsutomu Takahashi

Kazuyuki Shigeno

Hitoshi Minamiguchi

Junichi Miyatake

Hiroshi Handa

Yoshinobu Kanda

Minoru Yoshida

Shuichi Miyawaki

Shigeki Ohtake

Tomoki Naoe

Hitoshi Kiyoi

Itaru Matsumura

Yasushi Miyazaki

Affiliations

Soon will be listed here.

Abstract

Purpose: The Japan Adult Leukemia Study Group (JALSG) AML201 protocols are regimens for remission induction and consolidation chemotherapy of acute myeloid leukemia (AML) and have been widely accepted in Japan since 2001. Management of infectious complications during chemotherapy has a key role in the supportive care of AML patients.

Methods: By using case report forms collected in December 2001 and December 2005, we retrospectively analyzed the infectious complications in adult patients treated by using the JALSG AML201 protocols against AML (excluding promyelocytic leukemia).

Results: Of 980 patients, 80.2% experienced febrile neutropenia (FN), 8.3% bacteremia/fungemia, and 10.3% pulmonary infection at least once during remission-induction chemotherapy. Gram-positive bacteremia accounted for 65.1% of bacteremia/fungemia in 2001-2005, compared with 38.2% in 1987-1991 and 45.9% in 1992-1995. Of 750 patients, 81.9% experienced FN, 21.9% bacteremia/fungemia, and 9.1% pulmonary infection at least once during consolidation chemotherapy. During consolidation chemotherapy, bacteremia/fungemia and pulmonary infection were significantly more frequent in the high-dose cytarabine (HDAC) arm than in the conventional multiagent arm (25.9 vs. 17.9% and 12.7 vs. 7.7%, respectively). Invasive pulmonary aspergillosis accounted for 15.8% of pulmonary infections during remission induction and 19.7% during consolidation chemotherapy.

Conclusions: Our data suggest that patterns of infectious complications have changed between 1987 and 2005, possibly because of chemoprophylaxis with oral fluoroquinolones and improved diagnosis of invasive pulmonary aspergillosis by serum antigen analysis.

Citing Articles

Ethyl Acetate Extract from Romdoul () Fruit Induced Apoptosis in Human Promyelocytic Leukemia Cells.

Hoai Nga N, Long T, Ngoc T, Nguyen N, Thao D, Trinh N Glob Adv Integr Med Health. 2024; 13:27536130241296826.

PMID: 39494213 PMC: 11528603. DOI: 10.1177/27536130241296826.

Toxicity and outcome of adults with acute myeloid leukemia receiving consolidation with high-dose cytarabine.

Lopes L, Nucci M, Portugal R Hematol Transfus Cell Ther. 2023; 46(4):397-401.

PMID: 37684163 PMC: 11451373. DOI: 10.1016/j.htct.2023.07.007.

Microbiology and prognostic prediction model of bloodstream infection in patients with hematological malignancies.

Wang J, Wang M, Zhao A, Zhou H, Mu M, Liu X Front Cell Infect Microbiol. 2023; 13:1167638.

PMID: 37457950 PMC: 10347389. DOI: 10.3389/fcimb.2023.1167638.

Infectious complications of induction treatment for acute myeloid leukaemia using the "7 + 3" protocol without antibiotic prophylaxis - 15 years of experience of one clinical site.

cernan M, Szotkowski T, Hubacek J, Kolar M, Faber E, Indrak K Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2022; 167(3):236-245.

PMID: 35258041 DOI: 10.5507/bp.2022.010.

Difference of compliance rates for the recommendations in Japanese Guideline on Febrile Neutropenia according to respondents' attributes: the second report on a questionnaire survey among hematology-oncology physicians and surgeons.

Akiyama N, Okamura T, Yoshida M, Kimura S, Yano S, Yoshida I Support Care Cancer. 2022; 30(5):4327-4336.

PMID: 35094140 PMC: 8942955. DOI: 10.1007/s00520-022-06834-9.

References

Freifeld A, Bow E, Sepkowitz K, Boeckh M, Ito J, Mullen C . Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2011; 52(4):e56-93. DOI: 10.1093/cid/cir073. View

Ohtake S, Miyawaki S, Kiyoi H, Miyazaki Y, Okumura H, Matsuda S . Randomized trial of response-oriented individualized versus fixed-schedule induction chemotherapy with idarubicin and cytarabine in adult acute myeloid leukemia: the JALSG AML95 study. Int J Hematol. 2010; 91(2):276-83. DOI: 10.1007/s12185-009-0480-5. View

Fujita H, Yoshida M, Miura K, Sano T, Kito K, Takahashi M . Management of infection in patients with acute leukemia during chemotherapy in Japan: questionnaire analysis by the Japan Adult Leukemia Study Group. Int J Hematol. 2009; 90(2):191-198. DOI: 10.1007/s12185-009-0367-5. View

Garnica M, Nouer S, Pellegrino F, Moreira B, Maiolino A, Nucci M . Ciprofloxacin prophylaxis in high risk neutropenic patients: effects on outcomes, antimicrobial therapy and resistance. BMC Infect Dis. 2013; 13:356. PMC: 3729823. DOI: 10.1186/1471-2334-13-356. View

Ohno R, Kobayashi T, Tanimoto M, Hiraoka A, Imai K, Asou N . Randomized study of individualized induction therapy with or without vincristine, and of maintenance-intensification therapy between 4 or 12 courses in adult acute myeloid leukemia. AML-87 Study of the Japan Adult Leukemia Study Group. Cancer. 1993; 71(12):3888-95. DOI: 10.1002/1097-0142(19930615)71:12<3888::aid-cncr2820711216>3.0.co;2-g. View

Ohtake S, Miyawaki S, Fujita H, Kiyoi H, Shinagawa K, Usui N . Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study. Blood. 2010; 117(8):2358-65. DOI: 10.1182/blood-2010-03-273243. View

Kimura S, Fujita H, Kato H, Hiramoto N, Hosono N, Takahashi T . Management of infection during chemotherapy for acute leukemia in Japan: a nationwide questionnaire-based survey by the Japan Adult Leukemia Study Group. Support Care Cancer. 2017; 25(11):3515-3521. DOI: 10.1007/s00520-017-3775-8. View

Kobayashi T, Miyawaki S, Tanimoto M, Kuriyama K, Murakami H, Yoshida M . Randomized trials between behenoyl cytarabine and cytarabine in combination induction and consolidation therapy, and with or without ubenimex after maintenance/intensification therapy in adult acute myeloid leukemia. The Japan Leukemia Study Group. J Clin Oncol. 1996; 14(1):204-13. DOI: 10.1200/JCO.1996.14.1.204. View

Miyawaki S, Ohtake S, Fujisawa S, Kiyoi H, Shinagawa K, Usui N . A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 Study. Blood. 2010; 117(8):2366-72. DOI: 10.1182/blood-2010-07-295279. View

10.

Klastersky J, de Naurois J, Rolston K, Rapoport B, Maschmeyer G, Aapro M . Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Ann Oncol. 2016; 27(suppl 5):v111-v118. DOI: 10.1093/annonc/mdw325. View

11.

Becker K, Heilmann C, Peters G . Coagulase-negative staphylococci. Clin Microbiol Rev. 2014; 27(4):870-926. PMC: 4187637. DOI: 10.1128/CMR.00109-13. View

12.

Yoshida M, Ohno R . Current antimicrobial usage for the management of infections in leukemic patients in Japan: results of a survey. Clin Infect Dis. 2004; 39 Suppl 1:S11-4. DOI: 10.1086/383044. View

13.

Miyawaki S, Tanimoto M, Kobayashi T, Minami S, Tamura J, Omoto E . No beneficial effect from addition of etoposide to daunorubicin, cytarabine, and 6-mercaptopurine in individualized induction therapy of adult acute myeloid leukemia: the JALSG-AML92 study. Japan Adult Leukemia Study Group. Int J Hematol. 1999; 70(2):97-104. View

14.

Masaoka T . Evidence-based recommendations for antimicrobial use in febrile neutropenia in Japan: executive summary. Clin Infect Dis. 2004; 39 Suppl 1:S49-52. DOI: 10.1086/383054. View

15.

Yoshida M, Akiyama N, Fujita H, Miura K, Miyatake J, Handa H . Analysis of bacteremia/fungemia and pneumonia accompanying acute myelogenous leukemia from 1987 to 2001 in the Japan Adult Leukemia Study Group. Int J Hematol. 2011; 93(1):66-73. DOI: 10.1007/s12185-010-0746-y. View

16.

Gafter-Gvili A, Fraser A, Paul M, Vidal L, Lawrie T, van de Wetering M . Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. Cochrane Database Syst Rev. 2012; 1:CD004386. PMC: 4170789. DOI: 10.1002/14651858.CD004386.pub3. View

17.

Syrjala H, Ohtonen P, Kinnunen U, Raty R, Elonen E, Nousiainen T . Blood stream infections during chemotherapy-induced neutropenia in adult patients with acute myeloid leukemia: treatment cycle matters. Eur J Clin Microbiol Infect Dis. 2010; 29(10):1211-8. DOI: 10.1007/s10096-010-0984-1. View

18.

Miyawaki S, Sakamaki H, Ohtake S, Emi N, Yagasaki F, Mitani K . A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan.... Cancer. 2005; 104(12):2726-34. DOI: 10.1002/cncr.21493. View

19.

Muto C, Pokrywka M, Shutt K, Mendelsohn A, Nouri K, Posey K . A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol. 2005; 26(3):273-80. DOI: 10.1086/502539. View

20.

Hamilton B, Copelan E . Concise review: the role of hematopoietic stem cell transplantation in the treatment of acute myeloid leukemia. Stem Cells. 2012; 30(8):1581-6. DOI: 10.1002/stem.1140. View